Publication: Design and synthesis of berberine derivatives as pcsk9 inhibitorfor lipid reduction
1
1
Issued Date
2021-08-16
Resource Type
Language
eng
File Type
application/pdf
Access Rights
Open Access
Rights
ผลงานนี้เผยแพร่ภายใต้ สัญญาอนุญาตครีเอทีฟคอมมอนส์แบบ แสดงที่มา-ไม่ใช้เพื่อการค้า-ไม่ดัดแปลง 4.0 (CC BY-NC-ND 4.0)
Rights Holder(s)
Srinakharinwirot University
Suggested Citation
Munchalika Jaitrong, มัญชลิกา ใจตรง (2021). Design and synthesis of berberine derivatives as pcsk9 inhibitorfor lipid reduction. Retrieved from: https://hdl.handle.net/20.500.14740/54224
Alternative Title(s)
การออกแบบและสังเคราะห์อนุพันธ์เบอร์เบอรีนให้เป็นตัวยับยั้ง PCSK9 เพื่อลดระดับไขมัน
Author(s)
Advisor(s)
Organization
Abstract
Nowadays, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) has become a new target for hypercholesterolemia treatment. PCSK9 is a crucial protein in Low-Density Lipoprotein cholesterol (LDL-C) metabolism by regulating the degradation of hepatic low-density lipoprotein receptors (LDLRs). Recently, two monoclonal antibodies (mAbs) PCSK9 inhibitors were approved by the Food and Drug Administration (FDA). However, no orally administrable small molecule has been approved. In addition, berberine (BBR), an isoquinoline alkaloid, has been reported to reduce total cholesterol levels and decrease PCSK9 expression with no severe side effects. Therefore, a novel series of BBR derivatives was designed based on molecular docking to serve as PCSK9 inhibitors in this work. The binding energy of BBR derivatives was investigated to confirm that all of the designed compounds showed better binding energy and stronger interaction than that of the parent BBR. An in silico study was also confirmed that most of the compounds fulfilled drug-likeness properties. Then, eight desired BBR derivatives were successfully synthesized starting from BBR via manich, demethylation, and alkylation reactions. Additionally, BBR derivatives were evaluated for the PCSK9 inhibition activity and the results showed that all of the compounds could down-regulate the PCSK9 expression. Especially, compounds 21 and 24 displayed a high inhibitory effect on PCSK9 by 20-fold higher activity than BBR. Furthermore, the naphthalene substitution at the C-13 position and alkoxy benzenesulfonamide substitution at the C-9 position of BBR significantly affected the inhibition of target enzyme activity. In summary, novel BBR derivatives could be proposed as potential PCSK9 inhibitors for hypercholesterolemia treatment.
-
-
Degree Name
MASTER OF SCIENCE (M.Sc.)
Degree Discipline
Department Of Chemistry
Degree Grantor(s)
Srinakharinwirot University